T790M-话题@MedSci

#T790M#

29篇内容 | 1798人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2188578, encodeId=ab2221885e82b, content=<a href='/topic/show?id=211e823029d' target=_blank style='color:#2F92EE;'>#肺腺癌#</a> <a href='/topic/show?id=154f3891074' target=_blank style='color:#2F92EE;'>#吉非替尼#</a> <a href='/topic/show?id=b0054454337' target=_blank style='color:#2F92EE;'>#奥希替尼#</a> <a href='/topic/show?id=98f91e05925' target=_blank style='color:#2F92EE;'>#T790M#</a> <a href='/topic/show?id=bd5a110612a2' target=_blank style='color:#2F92EE;'>#C797S#</a> <a href='/topic/show?id=9d0211138460' target=_blank style='color:#2F92EE;'>#19del#</a>, objectTitle=EGFR 19del/T790M/C797S顺式突变肺腺癌，成功获益吉非替尼联合奥希替尼, objectType=article, longId=814124, objectId=278a814124f8, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20221109/1668016299208_4754896.png, objectUrl=/article/show_article.do?id=278a814124f8, replyNumber=0, likeNumber=114, createdTime=2024-02-21, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=278a814124f8, moduleTitle=EGFR 19del/T790M/C797S顺式突变肺腺癌，成功获益吉非替尼联合奥希替尼, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=278a814124f8)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=2171231, encodeId=02cc21e1231d5, content=<a href='/topic/show?id=384b8220449' target=_blank style='color:#2F92EE;'>#肺癌#</a> <a href='/topic/show?id=b1fe8159270' target=_blank style='color:#2F92EE;'>#肠癌#</a> <a href='/topic/show?id=b0054454337' target=_blank style='color:#2F92EE;'>#奥希替尼#</a> <a href='/topic/show?id=98f91e05925' target=_blank style='color:#2F92EE;'>#T790M#</a>, objectTitle=开眼界，EGFR基因T790M的肠癌用肺癌靶向药奥希替尼治疗，真管用！, objectType=article, longId=802523, objectId=cd8a80252323, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/Random/medical-conference-P42ZDP5.jpg, objectUrl=/article/show_article.do?id=cd8a80252323, replyNumber=0, likeNumber=112, createdTime=2023-11-27, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=cd8a80252323, moduleTitle=开眼界，EGFR基因T790M的肠癌用肺癌靶向药奥希替尼治疗，真管用！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cd8a80252323)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1795272, encodeId=847b1e9527212, content=<a href='/topic/show?id=98f91e05925' target=_blank style='color:#2F92EE;'>#T790M#</a>, objectTitle=Ann Oncol：二线Osimertinib（奥希替尼）联合贝伐珠单抗并不能明显改善EGFR突变晚期NSCLC获得T790M突变患者的预后, objectType=article, longId=295378, objectId=2fbf2953e8d9, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=2fbf2953e8d9, replyNumber=0, likeNumber=98, createdTime=2022-02-23, rootId=0, userName=zhlpower, userId=c838337, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=2fbf2953e8d9, moduleTitle=Ann Oncol：二线Osimertinib（奥希替尼）联合贝伐珠单抗并不能明显改善EGFR突变晚期NSCLC获得T790M突变患者的预后, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=2fbf2953e8d9)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1795271, encodeId=f7a41e95271c7, content=<a href='/topic/show?id=98f91e05925' target=_blank style='color:#2F92EE;'>#T790M#</a>, objectTitle=Transl Lung Cancer Res: TP53共突变(TP53 mt+)对携带T790M耐药突变的EGFR mt+ NSCLC患者二线或以上使用奥希替尼治疗的影响, objectType=article, longId=295258, objectId=d4ed295258b0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d4ed295258b0, replyNumber=0, likeNumber=102, createdTime=2022-11-13, rootId=0, userName=zhlpower, userId=c838337, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d4ed295258b0, moduleTitle=Transl Lung Cancer Res: TP53共突变(TP53 mt+)对携带T790M耐药突变的EGFR mt+ NSCLC患者二线或以上使用奥希替尼治疗的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d4ed295258b0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1795266, encodeId=80a21e95266a8, content=<a href='/topic/show?id=98f91e05925' target=_blank style='color:#2F92EE;'>#T790M#</a>, objectTitle=Thorac Cancer：伴有EGFR-T790M突变的NSCLC患者，后续奥希替尼不同顺序治疗生存对比, objectType=article, longId=220998, objectId=36ac220998de, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=36ac220998de, replyNumber=0, likeNumber=83, createdTime=2022-08-09, rootId=0, userName=zhlpower, userId=c838337, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=36ac220998de, moduleTitle=Thorac Cancer：伴有EGFR-T790M突变的NSCLC患者，后续奥希替尼不同顺序治疗生存对比, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=36ac220998de)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1795270, encodeId=31131e9527086, content=<a href='/topic/show?id=98f91e05925' target=_blank style='color:#2F92EE;'>#T790M#</a>, objectTitle=J Thorac Oncol: 第三代EGFR-TKI lazertinib治疗T790m突变NSCLC患者疗效显著且安全可控, objectType=article, longId=293988, objectId=5aae293988cd, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5aae293988cd, replyNumber=0, likeNumber=92, createdTime=2022-07-30, rootId=0, userName=zhlpower, userId=c838337, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5aae293988cd, moduleTitle=J Thorac Oncol: 第三代EGFR-TKI lazertinib治疗T790m突变NSCLC患者疗效显著且安全可控, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5aae293988cd)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1795265, encodeId=ed7c1e9526535, content=<a href='/topic/show?id=98f91e05925' target=_blank style='color:#2F92EE;'>#T790M#</a>, objectTitle=Clin Cancer Res：第三代EGFR-TKI Abvertinib治疗EGFR T790M+ NSCLC的活性和安全性, objectType=article, longId=220039, objectId=bb122200396e, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bb122200396e, replyNumber=0, likeNumber=114, createdTime=2022-09-13, rootId=0, userName=zhlpower, userId=c838337, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bb122200396e, moduleTitle=Clin Cancer Res：第三代EGFR-TKI Abvertinib治疗EGFR T790M+ NSCLC的活性和安全性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bb122200396e)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1795269, encodeId=c8c41e9526950, content=<a href='/topic/show?id=98f91e05925' target=_blank style='color:#2F92EE;'>#T790M#</a>, objectTitle=BMC Cancer：EGFR 19外显子缺失插入突变患者一代EGFR-TKI治疗应答较好，获得T790M突变后奥希替尼治疗同样应答较好, objectType=article, longId=292019, objectId=0498292019ed, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0498292019ed, replyNumber=0, likeNumber=92, createdTime=2022-10-18, rootId=0, userName=zhlpower, userId=c838337, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0498292019ed, moduleTitle=BMC Cancer：EGFR 19外显子缺失插入突变患者一代EGFR-TKI治疗应答较好，获得T790M突变后奥希替尼治疗同样应答较好, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0498292019ed)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1795264, encodeId=1c781e9526462, content=<a href='/topic/show?id=98f91e05925' target=_blank style='color:#2F92EE;'>#T790M#</a>, objectTitle=Lung Cancer：序贯阿法替尼和奥希替尼治疗EGFR突变阳性的NSCLC患者并获得T790M:一项全球非干预性研究(UpSwinG), objectType=article, longId=218470, objectId=7b082184e0a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7b082184e0a7, replyNumber=0, likeNumber=86, createdTime=2022-02-04, rootId=0, userName=zhlpower, userId=c838337, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7b082184e0a7, moduleTitle=Lung Cancer：序贯阿法替尼和奥希替尼治疗EGFR突变阳性的NSCLC患者并获得T790M:一项全球非干预性研究(UpSwinG), moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7b082184e0a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1795268, encodeId=7fc41e9526804, content=<a href='/topic/show?id=98f91e05925' target=_blank style='color:#2F92EE;'>#T790M#</a>, objectTitle=J Thorac Oncol：Aumolertinib(HS-10296)治疗EGFR-T790M+晚期NSCLC患者的疗效和安全性：APOLLO研究, objectType=article, longId=221184, objectId=7716221184e3, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7716221184e3, replyNumber=0, likeNumber=76, createdTime=2022-02-14, rootId=0, userName=zhlpower, userId=c838337, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7716221184e3, moduleTitle=J Thorac Oncol：Aumolertinib(HS-10296)治疗EGFR-T790M+晚期NSCLC患者的疗效和安全性：APOLLO研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7716221184e3)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1795262, encodeId=86201e9526251, content=<a href='/topic/show?id=98f91e05925' target=_blank style='color:#2F92EE;'>#T790M#</a>, objectTitle=Lancet Respirat Med：三代酪氨酸激酶抑制剂Furmonertinib在EGFR T790M突变的NSCLC患者中的疗效可期！, objectType=article, longId=209220, objectId=b2172092201a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=b2172092201a, replyNumber=0, likeNumber=108, createdTime=2021-12-26, rootId=0, userName=zhlpower, userId=c838337, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=b2172092201a, moduleTitle=Lancet Respirat Med：三代酪氨酸激酶抑制剂Furmonertinib在EGFR T790M突变的NSCLC患者中的疗效可期！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=b2172092201a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1795267, encodeId=dc811e952670e, content=<a href='/topic/show?id=98f91e05925' target=_blank style='color:#2F92EE;'>#T790M#</a>, objectTitle=APOLLO研究：Aumolertinib在中国获批用于EGFR T790M阳性NSCLC患者, objectType=article, longId=221110, objectId=ba8922111014, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=ba8922111014, replyNumber=0, likeNumber=80, createdTime=2021-12-11, rootId=0, userName=zhlpower, userId=c838337, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=ba8922111014, moduleTitle=APOLLO研究：Aumolertinib在中国获批用于EGFR T790M阳性NSCLC患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=ba8922111014)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1795261, encodeId=828e1e95261eb, content=<a href='/topic/show?id=98f91e05925' target=_blank style='color:#2F92EE;'>#T790M#</a>, objectTitle=Nat Commun：EGFR T790M突变在晚期非小细胞肺癌中的临床影响, objectType=article, longId=209060, objectId=19bd20906089, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=19bd20906089, replyNumber=0, likeNumber=73, createdTime=2021-03-29, rootId=0, userName=zhlpower, userId=c838337, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=19bd20906089, moduleTitle=Nat Commun：EGFR T790M突变在晚期非小细胞肺癌中的临床影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=19bd20906089)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1795263, encodeId=a6401e95263ae, content=<a href='/topic/show?id=98f91e05925' target=_blank style='color:#2F92EE;'>#T790M#</a>, objectTitle=Lung Cancer：EGFR-T790M突变阳性非小细胞肺癌（NSCLC）奥希替尼进展后奥希替尼联合治疗仍有生存获益, objectType=article, longId=213493, objectId=fdd621349391, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=fdd621349391, replyNumber=0, likeNumber=106, createdTime=2022-01-23, rootId=0, userName=zhlpower, userId=c838337, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=fdd621349391, moduleTitle=Lung Cancer：EGFR-T790M突变阳性非小细胞肺癌（NSCLC）奥希替尼进展后奥希替尼联合治疗仍有生存获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=fdd621349391)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1795258, encodeId=2a601e95258c4, content=<a href='/topic/show?id=98f91e05925' target=_blank style='color:#2F92EE;'>#T790M#</a>, objectTitle=2019 WCLC ∣奥希替尼160mg为EGFR T790M突变阳性伴CNS转移NSCLC患者带来显著获益, objectType=article, longId=179499, objectId=164d1e9499e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=164d1e9499e1, replyNumber=0, likeNumber=92, createdTime=2020-08-08, rootId=0, userName=zhlpower, userId=c838337, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=164d1e9499e1, moduleTitle=2019 WCLC ∣奥希替尼160mg为EGFR T790M突变阳性伴CNS转移NSCLC患者带来显著获益, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=164d1e9499e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1795259, encodeId=da141e952597d, content=<a href='/topic/show?id=98f91e05925' target=_blank style='color:#2F92EE;'>#T790M#</a>, objectTitle=2019 WCLC ∣ 奥希替尼治疗T790M阳性伴罕见和/或复杂突变的晚期NSCLC，疗效显著, objectType=article, longId=179503, objectId=d2081e9503d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=d2081e9503d7, replyNumber=0, likeNumber=90, createdTime=2019-11-12, rootId=0, userName=zhlpower, userId=c838337, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=d2081e9503d7, moduleTitle=2019 WCLC ∣ 奥希替尼治疗T790M阳性伴罕见和/或复杂突变的晚期NSCLC，疗效显著, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d2081e9503d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1795260, encodeId=3d951e952608b, content=<a href='/topic/show?id=98f91e05925' target=_blank style='color:#2F92EE;'>#T790M#</a>, objectTitle=豪森药业第三代EGFR TKI在中国获批用于EGFR T790M突变型非小细胞肺癌的二线治疗, objectType=article, longId=190514, objectId=8e2119051451, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8e2119051451, replyNumber=0, likeNumber=77, createdTime=2020-11-24, rootId=0, userName=zhlpower, userId=c838337, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8e2119051451, moduleTitle=豪森药业第三代EGFR TKI在中国获批用于EGFR T790M突变型非小细胞肺癌的二线治疗, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8e2119051451)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1795256, encodeId=ac1b1e952561d, content=<a href='/topic/show?id=98f91e05925' target=_blank style='color:#2F92EE;'>#T790M#</a>, objectTitle=Radiology：对EGFR-TKI治疗后耐药的非小细胞肺癌中T790M突变阳性患者胸部CT特征的研究, objectType=article, longId=144828, objectId=bdde144828d7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bdde144828d7, replyNumber=0, likeNumber=80, createdTime=2019-01-05, rootId=0, userName=zhlpower, userId=c838337, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bdde144828d7, moduleTitle=Radiology：对EGFR-TKI治疗后耐药的非小细胞肺癌中T790M突变阳性患者胸部CT特征的研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bdde144828d7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1795255, encodeId=70731e9525531, content=<a href='/topic/show?id=98f91e05925' target=_blank style='color:#2F92EE;'>#T790M#</a>, objectTitle=Lung Cancer：高T790M 与EGFR突变比值与奥希替尼疗效相关, objectType=article, longId=129883, objectId=8c7d1298839d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8c7d1298839d, replyNumber=0, likeNumber=83, createdTime=2018-02-16, rootId=0, userName=zhlpower, userId=c838337, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8c7d1298839d, moduleTitle=Lung Cancer：高T790M 与EGFR突变比值与奥希替尼疗效相关, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8c7d1298839d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1795257, encodeId=bac61e9525789, content=<a href='/topic/show?id=98f91e05925' target=_blank style='color:#2F92EE;'>#T790M#</a>, objectTitle=【WCLC速递】拨云见日，未来可期：数据证实奥希替尼在继发T790M耐药和脑转移患者中疗效确切, objectType=article, longId=150187, objectId=c14115018eac, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c14115018eac, replyNumber=0, likeNumber=86, createdTime=2018-10-24, rootId=0, userName=zhlpower, userId=c838337, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c14115018eac, moduleTitle=【WCLC速递】拨云见日，未来可期：数据证实奥希替尼在继发T790M耐药和脑转移患者中疗效确切, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c14115018eac)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

T790M

2020-05-29

梅斯管理员

#肺腺癌# #吉非替尼# #奥希替尼# #T790M# #C797S# #19del#

EGFR 19del/T790M/C797S顺式突变肺腺癌，成功获益吉非替尼联合奥希替尼

2024-02-21发表于上海

梅斯管理员

#肺癌# #肠癌# #奥希替尼# #T790M#

开眼界，EGFR基因T790M的肠癌用肺癌靶向药奥希替尼治疗，真管用！

2023-11-27发表于上海

zhlpower

#T790M#

Ann Oncol：二线Osimertinib（奥希替尼）联合贝伐珠单抗并不能明显改善EGFR突变晚期NSCLC获得T790M突变患者的预后

2022-02-23

zhlpower

#T790M#

Transl Lung Cancer Res: TP53共突变(TP53 mt+)对携带T790M耐药突变的EGFR mt+ NSCLC患者二线或以上使用奥希替尼治疗的影响

2022-11-13

zhlpower

#T790M#

Thorac Cancer：伴有EGFR-T790M突变的NSCLC患者，后续奥希替尼不同顺序治疗生存对比

2022-08-09

zhlpower

#T790M#

J Thorac Oncol: 第三代EGFR-TKI lazertinib治疗T790m突变NSCLC患者疗效显著且安全可控

2022-07-30

zhlpower

#T790M#

Clin Cancer Res：第三代EGFR-TKI Abvertinib治疗EGFR T790M+ NSCLC的活性和安全性

2022-09-13

zhlpower

#T790M#

BMC Cancer：EGFR 19外显子缺失插入突变患者一代EGFR-TKI治疗应答较好，获得T790M突变后奥希替尼治疗同样应答较好

2022-10-18

zhlpower

#T790M#

Lung Cancer：序贯阿法替尼和奥希替尼治疗EGFR突变阳性的NSCLC患者并获得T790M:一项全球非干预性研究(UpSwinG)

2022-02-04

zhlpower

#T790M#

J Thorac Oncol：Aumolertinib(HS-10296)治疗EGFR-T790M+晚期NSCLC患者的疗效和安全性：APOLLO研究

2022-02-14

zhlpower

#T790M#

Lancet Respirat Med：三代酪氨酸激酶抑制剂Furmonertinib在EGFR T790M突变的NSCLC患者中的疗效可期！

2021-12-26

zhlpower

#T790M#

APOLLO研究：Aumolertinib在中国获批用于EGFR T790M阳性NSCLC患者

2021-12-11

zhlpower

#T790M#

Nat Commun：EGFR T790M突变在晚期非小细胞肺癌中的临床影响

2021-03-29

zhlpower

#T790M#

Lung Cancer：EGFR-T790M突变阳性非小细胞肺癌（NSCLC）奥希替尼进展后奥希替尼联合治疗仍有生存获益

2022-01-23

zhlpower

#T790M#

2019 WCLC ∣奥希替尼160mg为EGFR T790M突变阳性伴CNS转移NSCLC患者带来显著获益

2020-08-08

zhlpower

#T790M#

2019 WCLC ∣ 奥希替尼治疗T790M阳性伴罕见和/或复杂突变的晚期NSCLC，疗效显著

2019-11-12

zhlpower

#T790M#

豪森药业第三代EGFR TKI在中国获批用于EGFR T790M突变型非小细胞肺癌的二线治疗

2020-11-24

zhlpower

#T790M#

Radiology：对EGFR-TKI治疗后耐药的非小细胞肺癌中T790M突变阳性患者胸部CT特征的研究

2019-01-05

zhlpower

#T790M#

Lung Cancer：高T790M 与EGFR突变比值与奥希替尼疗效相关

2018-02-16

zhlpower

#T790M#

【WCLC速递】拨云见日，未来可期：数据证实奥希替尼在继发T790M耐药和脑转移患者中疗效确切

2018-10-24